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Abstract 1 
Antigenic mimicry is a fundamental tenet of structure-based vaccinology. Vaccine strategies for the 2 
human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its envelope spike (Env) due to 3 
its exposed location on the viral membrane and role in mediating infection. However, the virus has 4 
evolved to minimise the immunogenicity of conserved epitopes on the envelope spike. This principle 5 
is starkly illustrated by the presence of an extensive array of host-derived glycans which act to shield 6 
the underlying protein from antibody recognition. Despite these hurdles, a subset of HIV-infected 7 
individuals eventually develop broadly neutralising antibodies that recognise these virally-presented 8 
glycans. Effective HIV-1 immunogens are therefore likely to involve some degree of mimicry of both 9 
the protein and glycan components of Env. As such, considerable efforts have been made to 10 
characterise the structure of the envelope spike and its glycan shield. This review summarises the 11 
recent progress made in this field, with an emphasis on our growing understanding of the factors 12 
shaping the glycan shield of Env derived from both virus and soluble immunogens. We argue that 13 
recombinant mimics of the envelope spike are currently capable of capturing many features of the 14 
native viral glycan shield. Finally, we explore strategies through which the immunogenicity of Env 15 
glycans may be enhanced in the development of future immunogens. 16 
Keywords: human immunodeficiency virus, vaccinology, antibodies, glycosylation, structure 17 
Abbreviations/Glossary: HIV-1, human immunodeficiency virus type 1; Env, envelope spike; AIDS, 18 
acquired immune deficiency syndrome; bnAb(s), broadly neutralising antibody(ies); nAb(s), 19 
neutralising antibody(ies); gl-bnAb(s), germline-bnAb(s); CD4bs, CD4 binding site; CCR5, C-C 20 
chemokine receptor type 5; CXCR4, C-X-C chemokine receptor type 4; TF, transmitted/founder; EM, 21 
electron microscopy; PNGS, potential N-glycosylation sites; BCR, B cell receptor, IMP, intrinsic 22 
mannose patch; TAMP, trimer associated mannose patch; HCDR3, third heavy chain complementarity-23 
determining regions; CDR, complementarity-determining regions; LOS, lipooligosaccharides; SP, signal 24 
peptide; MPER, membrane proximal external region; TM, transmembrane region; CT, cytoplasmic tail; 25 
HR1/2, heptad repeat 1 or 2; NFL, native flexibly linked; SC, single-chain; UFO, uncleaved prefusion-26 
optimised; PBMC, peripheral blood mononuclear cell; PNS, peripheral nervous system; CHO, Chinese 27 
hamster ovary; HEK, human embryonic kidney; cGMP, current good manufacturing practices; Glc, 28 
glucose; Man, mannose; GlcNAc, N-acetylglucosamine; Gal, galactose; Fuc, fucose; Neu5Ac, N-29 
acetylneuraminic acid (sialic acid); GlcN, glucosamine; KDO, 2-keto-3-deoxy-D-manno-octulosonic 30 
acid; ER, endoplasmic reticulum; α-man I and II, α-mannosidase I and II; GnT I, N-31 
acetylglucosaminyltransferase I. 32 
33 
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1. Challenges facing HIV-1 vaccine design 34 
Vaccines typically contain or mimic parts or all of a pathogen, such as an attenuated strain or 35 
recombinant soluble surface protein, to prime the immune system to produce an effective response 36 
upon future exposure to that pathogen. This strategy has proved to be very successful in the past, 37 
famously resulting in the complete eradication of the smallpox virus [1], and more recently in a 38 
protective vaccine against Ebola virus [2]. Despite significant efforts, a vaccine capable of eliciting a 39 
protective response against the human immunodeficiency virus type 1 (HIV-1) has proved elusive [3]. 40 
Both antibodies and cytotoxic T lymphocytes are produced upon infection with HIV-1. 41 
However, the virus has evolved several features that undermine immunological control and 42 
eradication of infection, most notably, very high antigenic diversity and the establishment of a latent 43 
viral reservoir. While treatment with antiretroviral drugs can extend the life expectancy of infected 44 
individuals to near-normal [4, 5], drug-resistance has been documented for every class of 45 
antiretroviral currently in use [6], and treatment regimens are often accompanied by adverse side-46 
effects and low levels of adherence. Furthermore, cessation of therapy results in rapid viral rebound 47 
[7]. If left untreated, HIV-1 infection results in diminished numbers of CD4+ T cells (the major viral 48 
target cell), causing acquired immune deficiency syndrome (AIDS) and death. While HIV-1 cure 49 
strategies are an important and viable field of research [8], the development of an effective 50 
prophylactic vaccine remains a primary goal in the effort to control the HIV-1 pandemic. 51 
Analysis of the immune response of infected individuals has renewed optimism that a vaccine 52 
may be a tractable goal [9, 10]. A subset of HIV-1 infected patients are able to generate antibodies of 53 
sufficient breadth and potency to neutralise the vast majority of circulating HIV-1 isolates [11-13]. 54 
Although these broadly neutralising antibodies (bnAbs) are unable to clear the virus from the infected 55 
individual, they are able to protect non-human primates [14-25] and humanised mice [26-32] from 56 
viral challenge when passively administered. Importantly, these antibodies are protective at 57 
concentrations achievable by vaccination in other settings [15, 17]. Taken together, these 58 
observations provide some support for the hypothesis that a vaccine can be developed capable of 59 
generating a protective antibody response against HIV-1. 60 
All known bnAbs are directed against the envelope spike (Env) [33-35], the only viral protein 61 
on the virus surface (Fig. 1A). Therefore, while the contribution of T cells in the development of an 62 
antibody response is critical [36-38], considerable research efforts have been directed at the 63 
development of stable, recombinant mimics of the envelope spike in order to elicit a B cell response 64 
[39]. Central to this strategy is the hypothesis that antigenic mimicry of a vaccine candidate is essential 65 
for the induction of an antibody response against that antigen [37, 40]. However, HIV-1 has evolved 66 
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under immense selection pressure by the humoral immune system and consequently many of the 67 
most valuable bnAb epitopes are inherently poor immunogens. One manifestation of this is an 68 
extensive array of host-derived N-glycans which surrounds the envelope spike to create a largely 69 
immunologically ‘self’ glycan shield (Fig. 1B). While originally thought to protect the underlying protein 70 
surface from immune recognition, the discovery that many bnAbs can develop that recognise glycan 71 
epitopes has exposed the glycan shield itself as a potential target for vaccine design [41]. Scanlan et 72 
al. previously highlighted the apparent contradiction in that HIV-1 glycans have evolved as an 73 
adaptation for virus survival and yet have emerged as targets for vaccine design [42]. It is therefore 74 
important that Env-based immunogens are able to mimic effectively both the protein and glycan 75 
components of the envelope spike, though strategies that tackle the poor immunogenicity of the 76 
glycan epitopes are likely to be required. 77 
In order to inform the rational design of Env immunogens a detailed understanding of both 78 
the composition of the glycan shield, and the structural rules governing its formation are required. 79 
This review will discuss recent contributions to the field of HIV-1 vaccine design, specifically the 80 
principles governing HIV-1 glycosylation and how this can be used to help select candidate 81 
immunogens. We also discuss the strategies being explored with the aim of boosting the 82 
immunogenicity of Env-based vaccines. 83 
 84 
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Figure 1. Structure of the HIV-1 virion and the envelope spike. (A) Graphic depicting the structure of 85 
the HIV-1 virion. Approximately 14 envelope spikes are displayed on the surface of the virion (mean 86 
for one HIV-1 isolate), embedded into the host cell-derived lipid membrane [43]. (B) Model of a fully 87 
glycosylated envelope spike (glycans in cyan sticks) based on PDB: 5ACO [44]. Glycans were added 88 
according to Behrens et al., 2016 [45]. The envelope spike is a trimer of non-covalently associated 89 
gp120 (light grey) and gp41 (dark grey) heterodimers. The gp120 subunits contain the CD4 receptor 90 
and CCR5 or CXCR4 co-receptor binding sites. Upon binding, the trimer undergoes substantial 91 
conformational changes that enable the gp41 subunits to drive fusion of the viral and host cell 92 
membranes. The membrane proximal external region (MPER), transmembrane domain (TM) and 93 
cytoplasmic tail (CT) are not present on the structure and are shown for one protomer in cartoon along 94 
with the lipid membrane for orientation. (C) Left: Schematic representation of the primary structure 95 
of Env (top) and the soluble immunogen, BG505 SOSIP.664 (bottom). Variable regions (V1-5) are 96 
shown in colour, constant regions (C1-5) are shown in light grey, and gp41 is shown in dark grey. The 97 
envelope spike has approximately 25 potential N-glycosylation sites per gp120, and 4 per gp41 (cyan 98 
forks; mean across many isolates) [46]. SOSIP.664 modifications are annotated in magenta, with 99 
optional purification tag coloured green. FP = fusion peptide, HR1/2 = heptad repeat 1 and 2. Right: 100 
Model of a de-glycosylated envelope spike (as in B), with variable loops coloured accordingly. 101 
 102 
1.1 The antibody response  103 
Neutralising antibodies (nAbs) typically work by binding an antigen on the viral surface to prevent the 104 
virus from infecting the host cell, and correlate with protection in the majority of licensed vaccines 105 
[47]. As the only viral protein on the virion surface, and playing a key role in mediating infection, the 106 
envelope spike is the sole target for nAbs. However, several fundamental features of HIV-1 biology 107 
hinder the development of nAbs in both a vaccine and infection setting. The functional envelope spike 108 
is a trimer of non-covalently associated gp120-gp41 heterodimers (Fig. 1), generated by furin cleavage 109 
of a gp160 precursor polypeptide. Host cell tropism and attachment is mediated by the gp120 110 
subunits, which contain the CD4 receptor and co-receptor (CCR5 or CXCR4) binding sites. Once bound, 111 
substantial conformational changes enable the gp41 subunits to drive fusion of the viral and host cell 112 
membranes [48]. Antibodies capable of binding the spike in its functional conformation prevent this 113 
occurring. However, functional Envs are few and far between, with only approximately 14 spikes per 114 
viral particle (mean for one HIV-1 isolate) [43]. The wide spacing of the envelope spikes is 115 
disadvantageous for the host antibody response as B cells are more effectively activated by repetitive 116 
and organised structures [49]. 117 
The virus also produces an abundance of non-functional envelope spikes in the form of 118 
uncleaved gp160, and non-functional monomeric subunits such as soluble gp120 and gp41 stumps. 119 
These can arise either through the improper processing of the spike, or its later disintegration (Fig. 120 
1A). This ‘viral debris’ displays immunodominant epitopes that are either occluded or absent on the 121 
functional trimer (e.g. the inner surface of gp120), and acts to divert the host antibody response [50-122 
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55]. Thus, the initial antibody response, arising over the first few weeks of infection, is incapable of 123 
binding the functional envelope spike and is ‘non-neutralising’ [56].  124 
A further nAb evasion feature of HIV-1 is the relatively poor accessibility of its conserved 125 
epitopes. The CD4 binding site (CD4bs), for example, is a highly conserved region essential for 126 
infectivity and thus represents a potentially vulnerable site for antibody neutralisation. However, its 127 
recessed location within the trimer interface, surrounded by N-glycans, reduces the accessibility of 128 
this valuable collection of epitopes for nAb recognition. Interestingly, llamas and cows are capable of 129 
generating nAbs against the CD4bs region following immunisation with Env [57, 58]. Llamas naturally 130 
produce heavy-chain only antibodies that are much smaller than conventional antibodies, while cow 131 
antibodies contain very long third heavy chain complementarity-determining regions (HCDR3), some 132 
over 70 amino acids in length. The unusual architectures of these antibodies enable them to easily 133 
access the CD4bs, supporting a model of steric blocking for conventional IgG molecules. 134 
In contrast, highly variable regions occupy the more accessible regions of the trimer, providing 135 
yet another immunodominant diversion (Fig. 1C). Within a few months of infection patients readily 136 
develop autologous nAbs (i.e. antibodies capable of neutralising only the strain they were raised 137 
against), often directed at the variable loops 1, 2 and 3 (V1/V2 and V3) [59, 60]. Antibody-mediated 138 
selection pressure, combined with an error-prone viral reverse transcriptase, rapidly drives viral 139 
escape and results in extreme diversity [60]. Indeed, the genetic diversity of HIV-1 within an infected 140 
individual is comparable to the global genetic diversity of influenza in one year [46]. Thus, an effective 141 
vaccine against HIV-1 must not only induce nAbs, but antibodies with sufficient breadth of activity to 142 
neutralise the majority of circulating strains (bnAbs). 143 
The development of bnAbs is dependent on the activation of the appropriate naïve B cells by 144 
engaging their B cell receptor (BCR), i.e. the precursor bnAb, prior to affinity maturation of the B cell 145 
in the germinal centre by somatic hypermutation. The resulting bnAbs are often significantly mutated 146 
from their germline-encoded BCR [33]. However, this process is hindered by the low affinity of so-147 
called “germline”-bnAbs (gl-bnAbs) to the envelope spike. Consequently, many recombinant Env 148 
mimics also fail to bind gl-bnAbs [61-64], adding to the difficulties in eliciting bnAbs in a vaccine setting 149 
(Section 6.3).  150 
1.2 The glycan shield 151 
A contributing factor to the immunodominance of many of the non-neutralising and autologous 152 
neutralising epitopes, and the inability of Env to bind gl-bnAbs, is the presence of an array of N-glycans 153 
that mask much of the surface of the envelope spike (Fig. 1B). Each Env can have upwards of 90 154 
potential N-glycosylation sites (PNGS), with glycans comprising approximately half the trimer’s mass 155 
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[65]. The extensive N-glycosylation presents additional challenges for the host antibody response to 156 
overcome. The glycans are derived from the host’s own glycosylation machinery during Env synthesis 157 
and are therefore considered immunologically ‘self’. Auto-reactive B cells undergo strong negative 158 
selection during B cell development, constraining the development of potential anti-glycan antibodies 159 
[66]. Furthermore, glycoproteins tend to exist as heterogeneous populations, with a multitude of 160 
glycan structures decorating the same protein backbone,  thereby potentially reducing the antigenicity 161 
of each individual glycoform [67]. Lastly, protein-glycan interactions tend to have low binding affinities 162 
and often require multivalent interactions to overcome this [68]. The heavily glycosylated outer 163 
domain of gp120 has been dubbed the ‘silent face’ of HIV-1, due to the previous lack of antibodies 164 
described against this region [69]. 165 
The role of glycans in protecting HIV-1 from neutralising antibody responses has been well 166 
documented. The glycan shield constantly evolves to escape the host immune system, with the 167 
addition and deletion of glycan sites frequently used by the virus to escape nAb responses [70-72]. 168 
The ‘evolving glycan shield’ escape response is typified by the N332 glycan, which has been reported 169 
to shift from the N334 position and back again after the appearance of N332-dependent nAbs [70]. 170 
Furthermore, transmitted/founder (TF) viruses typically have fewer PNGS than chronic isolates [72-171 
75]. While this suggests there may be a fitness advantage to having fewer PNGS, a balance must then 172 
be struck between maintaining viral fitness and protecting vulnerable epitopes from the emerging nAb 173 
response. More recently a study by Wagh et al. reported that the addition of PNGS to fill holes in the 174 
glycan shield in vivo resulted in increased resistance to autologous nAbs [76]. Indeed, many in vitro 175 
studies have also reported the increased susceptibility of the virus to neutralisation upon removal of 176 
PNGS [77-81], which can often be rationalised by clashes observed between nAbs and glycans in 177 
structural studies [82, 83]. 178 
Despite the abovementioned challenges, approximately a third of infected individuals develop 179 
some level of bnAbs after a few years of infection [11-13]. Many bnAbs are able to either penetrate 180 
the glycan shield to bind protein surfaces or directly bind to Env glycans. Thus, while glycan shielding 181 
remains a potent immune evasion strategy, the discovery of numerous glycan-binding bnAbs, has 182 
highlighted the glycan shield as part of an attractive target for vaccine design [84]. The importance of 183 
the glycan shield in HIV-1 vaccine design has recently been underlined by Wagh et al., who observed 184 
that the development of bnAbs in infected individuals correlated with the completeness of the glycan 185 
shield at transmission [76]. 186 
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1.3 Instability of the viral spike 187 
Although bnAbs are increasingly being isolated from infected individuals, we are yet to elicit them in 188 
a vaccine setting in humans. Early vaccination strategies using recombinant, monomeric gp120 failed 189 
to confer protection [85-87], presumably due to the elicitation of antibodies directed against the 190 
aforementioned immunodominant non-neutralising epitopes (and/or the absence of gp41 and 191 
quaternary epitopes) [88]. The focus of HIV-1 vaccine research has now shifted to include the 192 
production of trimeric Env immunogens that display the majority of bnAb epitopes while minimising 193 
non-neutralising epitopes as much as possible, with the hope that these will be better able to induce 194 
a bnAb response [39]. However, the envelope spike is inherently unstable, reflecting its need to 195 
undergo substantial conformational changes during viral and host cell fusion. This has made the design 196 
of native-like immunogens particularly challenging (for an extensive review on the history and design 197 
of native-like Env trimers, see Sanders and Moore, 2017 [39]).  198 
The desire to remove the transmembrane region of the protein in order to generate soluble 199 
mimics often amplified trimer instability. Initial efforts to stabilise the trimer involved the removal or 200 
inactivation of the furin cleavage site to prevent gp120-gp41 dissociation, and/or the introduction of 201 
a trimerisation domain at the C-terminus to prevent separation of the three gp120-gp41 heterodimers 202 
[89, 90]. Although these approaches usually generated trimers, there was often an abundance of 203 
monomers, dimers, and higher-molecular weight aggregates, owing to the inappropriate formation of 204 
intermolecular disulphide bonds [91, 92]. These trimer constructs often displayed aberrantly folded 205 
gp120s due to intramolecular disulphide bond scrambling and non-native like quaternary structures 206 
as judged by peptide mapping, negative-stain electron microscopy (EM), hydrogen-deuterium 207 
exchange mass spectrometry and glycosylation analysis (Section 4.4). Perhaps most importantly, these 208 
trimers display non-native-like antigenicity [91-95] and are commonly referred to as ‘pseudotrimers’ 209 
to reflect their various non-native properties [39].  With hindsight it was therefore unsurprising that 210 
immunisation studies with pseudotrimers, not unlike monomeric gp120, failed to elicit nAbs with 211 
sufficient breadth or potency [96-98]. 212 
2. Protein mimicry in vaccine design 213 
The development of the SOSIP.664 platform transformed the field of native-like HIV-1 trimer design 214 
(Fig. 1C) [39]. These constructs retained the furin cleavage site, optimised for efficient cleavage, and 215 
relied on the introduction of a disulphide bond (‘SOS’) to covalently link the gp120 and gp41 subunits 216 
[99]. An additional point mutation in the gp41 subunits (I559P, ‘IP’) strengthened interactions 217 
between the three heterodimers by trapping the trimer in its pre-fusion conformation [100, 101], 218 
while truncation before the transmembrane region (‘.664’) ensured the solubility of the trimers and 219 
reduced aggregate formation [102]. A further point mutation (T332N) introduced a glycan site that 220 
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contributes to the epitope of many bnAbs. This format was first successfully applied to a clade A strain, 221 
BG505 [54], with the resulting ‘BG505 SOSIP.664’ trimers exhibiting both native-like structure [103] 222 
and antigenicity [54]. 223 
In recent years, an arsenal of native-like trimers has been produced. The ‘SOSIP’ format has 224 
since been applied to multiple strains, and mosaic and consensus sequences, though these often 225 
required further stabilising point mutations and disulphide bonds (either between gp120-gp41 and/or 226 
between protomers) [104-112]. Other native-like trimer formats focused on eliminating the 227 
requirement for furin cleavage (and therefore the need to co-express Env immunogens with furin 228 
encoding plasmids) in an attempt to simplify protein production strategies and DNA based vaccines. 229 
Native flexibly linked (NFL) and single-chain (SC) trimers achieved this feat by replacing the furin 230 
cleavage site with a flexible Gly-Ser linker [113, 114]. While the NFL and SC constructs both relied on 231 
the I559P point mutation to maintain the pre-fusion conformation, UFO (uncleaved prefusion-232 
optimised) constructs achieved this through a computational redesign of the  HR1 (heptad repeat 1) 233 
region [115]. The immunogenicity of many of the above mentioned native-like trimers have now been 234 
investigated in animal models [104, 107, 116-121], and have been reviewed by Sanders and Moore, 235 
2017 [39]. 236 
3. Display of bnAb epitopes by viral spike mimetics 237 
Native-like trimers are often assessed by their ability to bind bnAbs and not non-neutralising 238 
antibodies. The development of native-like soluble trimers enabled the characterisation of many bnAb 239 
epitopes through various biophysical techniques, such as X-ray crystallography and EM [122]. Broadly 240 
neutralising antibodies are generally categorised by their recognition of five distinct and largely 241 
conserved epitopes on the envelope spike: the CD4 binding site (CD4bs), the membrane proximal 242 
external region (MPER), and the N-glycans located at the gp120-gp41 interface, the outer domain of 243 
gp120, and on the V1/V2 loops at the trimer apex. However, recent advances in high throughput B cell 244 
screening have led to a dramatic increase in the identification of new bnAbs, and have subsequently 245 
revealed a continuum of epitopes spanning the entire surface of the trimer [34], including the majority 246 
of N-glycans (Fig. 2). The recent characterisation of bnAb VRC-PG05, which recognises glycans at 247 
positions N262, N295 and N448, could conceivably be the last class of bnAb to be identified as its 248 
discovery filled one of the few remaining gaps on the trimer surface [123]. 249 
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 250 
Figure 2. Broadly neutralising antibodies recognise protein-glycan epitopes. Model of a fully 251 
glycosylated BG505 SOSIP.664 trimer depicting the N-glycans that have been implicated in binding a 252 
variety of bnAbs (inset key). Glycans not present on the BG505 strain have been omitted, e.g.  35O22 253 
also recognises N-glycans at positions 230 and 241. Model based on PDB: 5ACO as in Figure 1, 254 
numbering according to the HXB2 reference sequence. CD4bs = CD4 binding site. 255 
 256 
The extent to which individual bnAbs depend on glycans for binding and neutralisation varies. 257 
At one extreme, 2G12 recognises an epitope comprised exclusively of N-glycans [124-130]. On the 258 
other hand, bnAbs against the CD4bs, for example, have evolved to either avoid or accommodate 259 
glycans that would otherwise occlude the underlying protein epitope [131]. Most bnAb epitopes 260 
occupy a midway point, with binding dependent on both protein and glycan components. 261 
The abundance of glycan-targeting bnAbs has earmarked N-glycans as important components 262 
of a future HIV-1 vaccine. Thus, there is a need for a detailed definition of the precise composition of 263 
the glycan shield on both viral Env and candidate immunogens. Additionally, an understanding of the 264 
principles controlling glycosylation will help guide the design of immunogens that are able to 265 
effectively mimic viral Env glycosylation, and, hopefully, elicit a broadly neutralising anti-glycan 266 
response. 267 
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3.1 Structure and development of broadly neutralising antibodies 268 
The development of bnAbs requires repeated rounds of viral escape and antibody maturation and can 269 
therefore take several years of infection to arise [70, 132, 133]. Their slow development may reflect 270 
the fact that bnAbs often depend on unusual antibody features in order to overcome the 271 
aforementioned challenges associated with the development of glycan recognition and neutralisation 272 
breadth. 273 
The glycan-targeting antibody, 2G12, overcomes low affinity protein-glycan interactions by 274 
exhibiting a unique domain-exchanged structure. Here, two heavy chain variable regions are 275 
exchanged to create a single Fab2 [127]. The resulting structure has an additional antigen binding site 276 
at the interface of the two arms, which allows for the binding of four Env glycans with high avidity 277 
[126, 127]. 278 
Many bnAbs, particularly those targeting the V1/V2 and outer domain glycans, contain very 279 
long HCDR3 sequences [134-139]. While the average length of human HCDR3 is 13 residues long [140], 280 
bnAb HCDR3s can contain upwards of 30 residues. This is particularly true of bnAbs targeting the 281 
glycans of the outer domain and V1/V2 loops, where long HCDR3 sequences allow the antibody to 282 
penetrate the glycan shield and make contact with the underlying protein surface. The HCDR3 of 283 
PGT145, for example, contains 33 residues, and penetrates the N160 glycan triad at the apex of the 284 
trimer to contact underlying protein residues from all three protomers [134]. For outer domain-285 
targeting bnAbs (e.g. PGT128 and PGT135), long HCDR3s allow penetration of the glycan shield to 286 
access the base of the V3 loop [136, 137]. In both examples, at least one glycan makes extensive 287 
interactions with the bnAb binding site. A similar phenomenon has been observed for bnAbs targeting 288 
the MPER, namely 4E10, where a long (20 residue), hydrophobic HCDR3 allows for contact with the 289 
lipid membrane as well as gp41 protein surface [139]. Often long HCDR3s are accompanied by post-290 
translational modifications, such as tyrosine sulphation, which have also been reported to contribute 291 
to binding and neutralisation [135]. 292 
Another feature present in many bnAbs is extensive somatic hypermutation [33]. Classically, 293 
antibodies accumulate such mutations in the antigen-contacting complementarity-determining 294 
regions (CDRs). However, bnAbs often require somatic mutations to the more conserved framework 295 
regions [141]. Although there is evidence that higher levels of somatic hypermutation correlate with 296 
increased breadth and potency in some bnAb lineages [142], this may be a consequence of the length 297 
of time of development rather than a necessity of bnAb activity. For instance, partially germline 298 
reverted forms of VRC01 and 10E8 bnAbs are still broad and potent neutralisers [143].  299 
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Poly- and auto-reactivity are also frequently associated with bnAbs [144-146]. These 300 
observations are somewhat unusual as both characteristics are negatively selected for during B cell 301 
development [66]. It has been hypothesised that conserved HIV-1 epitopes may mimic host proteins 302 
in order to avoid host antibody responses through the down-regulation of relevant B cells by host 303 
tolerance mechanisms [144, 145, 147]. A similar host immune evasion strategy has been reported for 304 
the pathogen Campylobacter jejuni, whose lipooligosaccharide (LOS) mimics the gangliosides of the 305 
host’s peripheral nervous system [148]. Despite these barriers, poly- and auto-reactive bnAbs are not 306 
uncommon, though their development may be dependent on prolonged exposure to the antigen, as 307 
several B cell tolerance checkpoints may need to be overcome. The elicitation of bnAbs through typical 308 
vaccination strategies may therefore prove challenging. 309 
4. Glycan mimicry in vaccine design 310 
The observation that glycan-dependent bnAbs can bind to soluble mimetics of the viral spike indicates 311 
that the glycans displayed by such immunogens are largely tolerated within the bnAb glycan specificity 312 
profile. However, given the nature of bnAbs, which have evolved to tolerate microheterogeneity of 313 
glycans, cross-reactivity does not necessarily indicate that the target glycans are precisely conserved 314 
between immunogen and virus. For example, some glycan specific bnAbs recognise the largely 315 
invariant base of the glycan [134, 149]. Furthermore, failure of an immunogen to bind a bnAb could 316 
be symptomatic of either a failure of protein mimicry, glycan mimicry, or both. For these reasons, 317 
there is significant interest in defining the glycosylation of both target viruses and candidate 318 
immunogens. Finally, detailed information about glycosylation will also help define the immunological 319 
ramifications of particular immunogen and viral glycoforms that may go beyond simply the display of 320 
particular glycan structures at a particular site. For example, are some glycoforms more inflammatory 321 
or immunogenic than others [150]? 322 
4.1 Understanding Env glycosylation processing 323 
The analysis of HIV-1 glycosylation is particularly challenging given the extensive heterogeneity 324 
displayed by glycoproteins, combined with the large number of PNGS on Env. Furthermore, isolating 325 
virally-derived Env in sufficient quantities for glycan analysis has proved difficult. Early glycan analyses 326 
were therefore generally performed on recombinant, monomeric gp120 [151-157], or trimeric Env 327 
constructs derived from pseudovirions [151, 158-160], membrane-associated trimers [161, 162], and 328 
recombinant, soluble trimers [45, 94, 121, 162-170]. These analyses soon revealed key aspects of Env 329 
glycosylation processing. Firstly, the Env glycan shield is heterogeneous. The gp120 subunit alone can 330 
contain upwards of 50 different glycan structures [45], attributed to the large number of glycan 331 
processing enzymes possessed by mammalian cells. Despite this heterogeneity, there always exists a 332 
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substantial population of under-processed, oligomannose-type glycans (Man5-9GlcNAc2). This glycan 333 
signature arises through steric constraints within the Env glycan shield that impede the actions of 334 
some of the host glycosylation enzymes (Section 4.3 and 4.4) [156, 158, 159, 171]. 335 
Many of the above glycan analyses focused on the analysis of enzymatically released N-336 
glycans. While this provides a useful readout of the overall glycosylation profile, no site-specific 337 
information can be gleaned. Such information, which involves the analysis of protease-digested 338 
glycopeptides, is valuable in order to elucidate the precise composition of bnAb epitopes. The 339 
development of the SOSIP.664 platform, combined with an advancement of mass spectrometric and 340 
chromatographic technologies enabled more in-depth, site-specific glycan analyses.  341 
We have previously published a quantitative, site-specific glycan analysis of the recombinant 342 
BG505 SOSIP.664 trimers [45]. This revealed that the oligomannose signature observed on Env was 343 
largely accounted for by several PNGS containing solely under-processed, oligomannose-type glycans, 344 
usually dominated by Man9GlcNAc2. The remaining sites contained either processed, complex-type 345 
glycans, or a mixed population. Mapping this information onto the structure of BG505 SOSIP.664 346 
illustrated how large regions of oligomannose-type glycans span across the outer domain of gp120, 347 
while complex-type glycans occupied sites at the periphery of the trimer, particularly on the gp41 348 
subunits (Fig. 3). 349 
 350 
 351 
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 352 
Figure 3. Principles controlling Env glycosylation. Site-specific glycan analysis of recombinant BG505 353 
SOSIP.664 [45, 163, 168, 172] and virally-derived BG505 Env [173, 174] has revealed clusters of glycans 354 
displaying under-processed, oligomannose-type glycans (green). These are largely located on the 355 
outer domain of gp120 (forming the intrinsic mannose patch) and at the trimer apex and protomer 356 
interfaces (forming the trimer associated mannose patch). Model according to Figure 1. (A) The 357 
quaternary protein structure of native-like trimers imposes steric constraints on the host’s 358 
glycosylation enzymes, resulting in an increase in the amount of oligomannose-type glycans at sites 359 
near the protomer interfaces (red/orange), compared to that of monomeric or non-native trimeric 360 
Env [168]. (B) Irrespective of the mature Env peptide sequence, the presence of a signal peptide (SP) 361 
from a transmitted/founder (TF) viral isolate results in an increase in oligomannose-type glycosylation, 362 
while a chronic-stage signal peptide results in increased complex-type glycosylation. The signal 363 
peptide influences Env trafficking, folding and retention through the ER [175]. (C) Modelling the ER α-364 
mannosidase I (cyan, PDB: 5KIJ) on to its substrate glycan (green) reveals extensive clashes with 365 
neighbouring glycans (red) sufficient to explain the formation of the intrinsic mannose patch [171]. 366 
(D) It is hypothesised that membrane-bound Env constructs display elevated glycosylation processing 367 
as they exhibit a different topology relative to the membrane-bound enzymes compared to soluble 368 
constructs, which are released into the lumen of the ER [173, 174]. Schematic of a membrane-bound 369 
glycan processing enzyme, based on the structure of a sialyltransferase (PDB: 6APL). (E) While the 370 
processing of many Env glycans is limited by protein-directed steric constraints, the fate of others is 371 
dependent on the glycosylation enzymes possessed by the host cell. The gp41 from BG505 SOSIP.664 372 
expressed in Chinese hamster ovary (CHO) cells displays increased sialylation compared to the same 373 
protein expressed in human embryonic kidney (HEK) cells [94]. 374 
 375 
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The Paulson laboratory employed a complementary site-specific workflow to analyse BG505 376 
SOSIP.664 trimers. By sequential digestion of glycopeptides with Endoglycosidase H (to cleave 377 
oligomannose-/hybrid-type glycans, leaving a GlcNAc residue) and Peptide-N-Glycosidase F in the 378 
presence of 18O-water (to cleave the remaining complex-type glycans and convert the Asn to an 18O-379 
labelled Asp), they were able to generate novel mass signatures for each category of glycan: +203 Da 380 
for oligomannose-/hybrid-type, +3 Da for complex-type glycans, and +0 for unoccupied peptides. Their 381 
data were in very close agreement to our earlier analysis. This classification method is very powerful 382 
for low abundance samples (as heterogeneous glycopeptides become grouped as a single peptide), 383 
although information on the exact composition of glycan sites is not captured. 384 
In some instances, the detail obtained from intact glycopeptide analysis may explain < 100% 385 
neutralisation plateaus observed by some bnAbs [176, 177]. For instance, PGT135 is only able to 386 
neutralise around 85% of BaL pseudoviruses [176]. This bnAb recognises predominantly glycans at 387 
N332, N386, and N392 (Fig. 2) [137]. Site-specific analysis of the N392 PNGS on recombinant gp120BaL 388 
(subscript denotes strain) revealed the majority of glycans at this site to be Man8GlcNAc2 structures, 389 
with a secondary population of Man9GlcNAc2 [176]. In line with this, a crystal structure of the PGT135 390 
Fab bound to a gp120JR-FL core shows the N392 site to be occupied by a Man8GlcNAc2 structure [137]. 391 
Modelling an additional mannose residue to this glycan (to give Man9GlcNAc2) revealed steric clashes 392 
with the bnAb [137]. Furthermore, it has been shown that PGT135 is unable to neutralise pseudovirus 393 
displaying predominantly Man9GlcNAc2 structures [137]. Thus, Man9GlcNAc2 at the N392 site seems 394 
unoptimal for PGT135 binding, and the site-specific presence of this structure may account for the 395 
observed neutralisation plateaus.  396 
4.2 Immunogen mimicry of viral glycosylation 397 
Recent progress in the production and purification of HIV-1 virions has enabled the glycosylation 398 
analysis of virally-derived Env. The Dell laboratory presented a qualitative analysis of gp120BaL 399 
glycosylation derived from virions produced in a human lymphoid cell line [178]. In line with analysis 400 
of SOSIP.664 trimers, 15 of the 24 PNGS contained solely oligomannose-type structures, although the 401 
relative abundances of each glycoform were not determined. The remaining nine contained either 402 
complex-type structures or mixed populations [178]. 403 
We have since performed site-specific glycan analysis on gp120BG505 isolated from virions 404 
expressed in a similar lymphoid cell line [173]. This allowed for a comparison with BG505 SOSIP.664 405 
trimers expressed in both human embryonic kidney (HEK) cells (as per previous analyses), and under 406 
equivalent conditions to current Good Manufacturing Practices (cGMP) in a Chinese hamster ovary 407 
(CHO) cell line. The analysis revealed that sites occupied by exclusively oligomannose-type glycans on 408 
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virally-derived Env were largely conserved on recombinant SOSIP.664s. This is reassuring considering 409 
a large proportion of glycan-targeting bnAbs recognise the oligomannose-type glycans at these sites 410 
(Fig. 2). However, there were some key differences between virally-derived and recombinant Envs. 411 
Namely, virally-derived Envs displayed increased levels of glycosylation processing, both in terms of 412 
the relative amount of complex-type glycosylation, and also the structures present (i.e. complex-type 413 
glycans on virally-derived Envs were more branched). This discrepancy was generally attributed to 414 
several complex-type PNGS on virally-derived Env that contained mixed populations of glycans on the 415 
SOSIP.664 trimers. We propose this is due to the membrane-bound nature of virally-derived Envs and 416 
will discuss this further in Section 4.6. 417 
The Paulson laboratory have also compared the glycosylation of virally-derived Env from three 418 
strains (JR-FL, BG505, and B41), produced in peripheral blood mononuclear cells (PBMCs), with their 419 
corresponding SOSIP.664 trimers, produced in HEK cells, using their aforementioned site-specific 420 
classification method [174]. Their results were in general agreement with our observations that mixed 421 
sites on SOSIP.664 trimers tended to be fully processed on the virally-derived Env. Thus, while there 422 
is some differential processing between viral and recombinant Env, many key bnAb epitopes are 423 
conserved. In terms of immunogen design, it is currently unknown whether absolute mimicry of viral 424 
glycosylation is required. This is likely to depend upon the specific epitope targeted, for example if the 425 
epitope mainly comprises the conserved base of the glycan. 426 
4.3 Glycan clustering and the intrinsic mannose patch 427 
This abundance of oligomannose-type glycans on Env is somewhat unusual given the virus derives its 428 
glycan shield from the host cell glycosylation machinery. This typically follows a highly ordered 429 
pathway whereby oligomannose-type precursors are trimmed and rebuilt as complex- and/or hybrid-430 
type glycans (Fig. 4). Two hypotheses existed as to why Env glycosylation diverges from that typically 431 
observed on mammalian glycoproteins. Either a proportion of Env glycoproteins are exiting the 432 
glycosylation pathway before encountering the later enzymes, or steric constraints exist within Env 433 
that are preventing complete processing by the earlier enzymes, or a combination of the two. Several 434 
pieces of evidence support the model of steric hindrance. 435 
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 436 
Figure 4. Overview of the mammalian N-glycosylation pathway. The envelope spike is extensively 437 
glycosylated by the host cell, which typically follows a highly ordered pathway. As the protein is 438 
translated, a Glc3Man9GlcNAc2 (Glc = glucose, Man = mannose, GlcNAc = N-acetylglucosamine) 439 
precursor is transferred en bloc to Asn residues within the N-glycan consensus sequence Asn-X-Thr/Ser 440 
(where X is any amino acid except Pro). As the protein is folded the three terminal glucose residues are 441 
removed to give rise to a glycoprotein displaying homogenous Man9GlcNAc2 structures. This is then 442 
further trimmed by endoplasmic reticulum (ER)- and Golgi apparatus-resident α-mannosidases to give 443 
rise to Man5GlcNAc2. Steric constraints within Env limit the actions of these early enzymes resulting in 444 
a population of under-processed oligomannose-type glycans. The addition of a β1-2-linked GlcNAc 445 
residue to Man5GlcNAc2 structures initiates cell-specific diversification to a variety of hybrid- and 446 
complex-type structures, through additional processing and/or trimming. α-man I and II = α-447 
mannosidase I and II, GnT I = N-acetylglucosaminyltransferase I, Gal = galactose, Fuc = fucose, Neu5Ac 448 
= N-acetylneuraminic acid (sialic acid). Glycan structures are depicted in symbols according to the 449 
Consortium for Functional Glycomics nomenclature, with linkage information according to Oxford 450 
nomenclature, as shown in the key. 451 
 452 
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Firstly, a proportion of oligomannose-type glycans are resistant to endoplasmic reticulum (ER) 453 
α-mannosidase I (the enzyme responsible for trimming Man9GlcNAc2 to Man8GlcNAc2, Fig. 4) digestion 454 
in vitro [159]. Expressing gp120 with kifunensine (an α-mannosidase I inhibitor) generates a 455 
glycoprotein bearing almost exclusively Man9GlcNAc2 structures, replicating the immature 456 
glycoprotein found in the early ER. Kinetic analysis of the hydrolysis of Man9GlcNAc2 to Man8GlcNAc2 457 
revealed approximately half of the Man9GlcNAc2 to be rapidly trimmed to Man8GlcNAc2, with the 458 
remaining Man9GlcNAc2 processed at a much slower rate. However, there remained a proportion of 459 
Man9GlcNAc2 (~ 30%) that could not be hydrolysed, even after exhaustive digestion. The resistance of 460 
these glycans to digestion in vitro supports the model of steric hindrance, likely caused by the high 461 
density of glycans on gp120 preventing α-mannosidases accessing their substrate glycans. 462 
Each gp120 subunit contains between 18 and 33 (median 25) PNGS [46]. To elucidate whether 463 
glycan density is the limiting factor preventing complete processing of the glycan shield, the number 464 
of PNGS on the outer domain of gp120 were correlated with the abundance of oligomannose-type 465 
glycans on sequences isolated from an individual over the course of infection, and on a cross-clade 466 
panel of 29 strains [157]. In both instances, a strong correlation was observed. This correlation was 467 
not seen when comparing the abundance of oligomannose-type glycans with the total number of 468 
PNGS on gp120 for the cross-clade panel (though it was for the infected patient sequences) suggesting 469 
that the incomplete processing observed on gp120 is driven by local glycan density, rather than overall 470 
glycan number. Similarly, Stewart-Jones et al. observed the number of glycan processing steps to be 471 
significantly lower for ‘crowded’ glycans (those with more than 15 PNGS within a 50Å radius) than for 472 
‘dispersed’ glycans (those with fewer than 15 PNGS within a 50Å radius) [149]. 473 
 The extent to which individual glycans contribute to the steric hindrance of glycosylation 474 
enzymes was investigated by the systematic site-directed mutagenesis of all the PNGS on gp120BaL, by 475 
mutating each Asn within the glycosylation sequon to Ala [156].  Although the removal of individual 476 
sites did not have a severe effect on the abundance of oligomannose-type glycans, several site 477 
deletions resulted in a larger than expected loss of Man9GlcNAc2, often accompanied by a 478 
compensatory increase in the lower oligomannose species, Man5-8GlcNAc2. The glycan sites 479 
accounting for the largest decrease in Man9GlcNAc2 generally mapped to the outer domain of gp120, 480 
further supporting a model whereby localised glycan clustering is sterically hindering early 481 
glycosylation processing. Thus, the loss of a PNGS within such clusters would increase the accessibility 482 
of neighbouring glycans so that multiple nearby glycans exhibit increased processing. In further 483 
support of this hypothesis, it has recently been confirmed by site-specific glycan analysis that the 484 
disruption in glycan processing upon the loss of a PNGS is largely limited to those sites adjacent to the 485 
missing glycans [179].  486 
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Thus, while the glycan structures present on most glycoproteins are determined by the host 487 
cell, HIV-1 is able to partly modulate its glycosylation processing through the number and position of 488 
PNGS, as determined by the viral sequence. The number of PNGS on Env are conserved both across 489 
clades and longitudinally throughout infection [157, 158]. The resulting high glycan density on Env 490 
(and gp120 in particular) limits the actions of α-mannosidases and results in a large population of 491 
oligomannose-type glycans. This principle is illustrated in a model of the ER α-mannosidase I enzyme 492 
binding a substrate Man9GlcNAc2 glycan on the outer domain of gp120, which reveals extensive 493 
clashes with the surrounding glycans [171]. A similar phenomenon has been observed on the 494 
glycoprotein complex of Lassa virus, which also exhibits high localised glycan density resulting in under 495 
processed oligomannose-type clusters [180]. The oligomannose-type glycans of gp120 are therefore 496 
an inherent feature of the glycoprotein, known as the ‘intrinsic mannose patch’ (IMP), and to some 497 
extent all Env constructs will display this glycan signature (Fig. 5). Encouragingly, many of the 498 
aforementioned glycan-targeting bnAbs recognise the oligomannose-type glycans of the IMP. The 499 
overall resilience of the oligomannose population to sequence variation, and its presence on both 500 
immunogens and viral Env, supports this feature as a conserved target for vaccine design.   501 
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 502 
Figure 5. Glycan clustering and protein structure limit glycosylation processing on HIV-1. 503 
Quantitative glycan analysis of monomeric gp120, pseudotrimers, native-like trimers and virally-504 
derived Env. For comparison, data for both gp120 and gp140 (gp120 + truncated gp41) from native-505 
like trimers have been included, only data for virally-derived gp120 was available [168, 173]. Each 506 
construct is based on the BG505 sequence containing the T332N mutation. Glycans were 507 
enzymatically released, fluorescently labelled, and analysed by hydrophilic interaction liquid 508 
chromatography-ultra performance liquid chromatography. Oligomannose-type glycans were 509 
quantified by their susceptibility to digestion with Endoglycosidase H. The chromatograms reveal a 510 
population of oligomannose-type glycans (green) intrinsic to all Env constructs, termed the intrinsic 511 
mannose patch (IMP). Only native-like trimers and virally-derived Envs display the additional trimer-512 
associated mannose patch (TAMP) signature, attributed to additional steric protection from 513 
processing. 514 
 515 
4.4 Protein structure and the trimer associated mannose patch 516 
As the focus of immunogen design shifted from monomeric gp120 toward trimeric Env, so did the 517 
requirement to categorise glycans from native-like immunogens. It had been observed that trimeric 518 
Envs often displayed even higher levels of under-processed oligomannose-type glycosylation [94, 158, 519 
159, 168]. The discrepancy in the abundance of oligomannose-type structures between monomeric 520 
and trimeric Env suggests that these structures are derived from an additional mechanism to the one 521 
driving the formation of the IMP. It was hypothesised that the ‘trimer associated mannose patch’ 522 
(TAMP) arose due to glycan-glycan and glycan-protein interactions at the protomer interface further 523 
sterically restricting processing enzymes [41, 158, 159]. 524 
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Quantitative glycan analysis soon revealed that the TAMP glycan signature was only present 525 
on native-like trimers, with non-native pseudotrimers often displaying glycosylation patterns similar 526 
to that of monomeric gp120 (Fig. 5) [92, 94, 168]. Negative-stain EM revealed that non-native 527 
pseudotrimers often form open, irregular structures, in stark contrast to the well-ordered, propeller 528 
shaped format of native-like trimers [92, 94, 171]. This structural difference is sufficient to explain the 529 
discrepancy in glycosylation, as open, irregular structures lack the additional steric protection of 530 
native-like trimers and allow for more complete glycan processing. Thus, although most Env proteins 531 
have a population of oligomannose-type glycans atypical of mammalian glycosylation, only native-like 532 
trimers display the additional TAMP signature. As such, glycosylation profiling is becoming a widely-533 
adopted tool that can be used to readily distinguish between native-like and misfolded trimers and 534 
guide the selection of immunogens [181]. 535 
Site-specific glycan analysis was applied to sequence-matched gp120BG505, uncleaved 536 
pseudotrimers, and native-like, BG505 SOSIP.664 trimers. The results revealed for the first time the 537 
individual PNGS that contribute to the TAMP. As hypothesised, sites located at the protomer 538 
interfaces on the native-like BG505 SOSIP.664 trimers displayed restricted glycan processing 539 
compared to both the pseudotrimers and monomeric gp120 (Fig. 3A). This was most significant at sites 540 
N156, N160, N197 and N276 which had > 40 percentage point increase in oligomannose-type glycans 541 
on BG505 SOSIP.664 compared to gp120 [168]. 542 
Crucially, in support of the native-like configuration of SOSIP.664 trimers, the TAMP signature 543 
is present on both virally-derived Envs and native-like trimers (Fig. 5), though it is somewhat smaller 544 
on viral Env [173]. This is likely due to ‘TAMP sites’ N197 and N276 displaying predominantly complex-545 
type glycosylation on viral Env [173, 174]. The N156 and N160 ‘TAMP sites’ are, however, conserved 546 
oligomannose-type sites in most instances [173, 174]. The N160 site has been reported as a complex-547 
type site in JR-FL virions, highlighting potential strain-specific differences [174]. 548 
4.5 Cell-specific glycosylation 549 
While the abundant population of oligomannose-type glycans observed on Env are attributed to steric 550 
constraints imposed by the protein itself, the more accessible regions of the glycoprotein are subject 551 
to processing by the host cell’s glycosylation pathway. Such processing is cell type-specific, dependent 552 
on the repertoire of glycosidases and glycosyltransferases expressed by the host cell [182]. 553 
A comparative analysis of BG505 SOSIP.664 derived from CHO cells and HEK cells illustrates 554 
the nature of protein- and cell-directed Envelope glycosylation [94]. Both CHO and HEK-derived 555 
material display similar levels of protein-directed glycosylation: oligomannose-type glycans account 556 
for 55 and 56% of the total glycan pool, respectively, with individual oligomannose species exhibiting 557 
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similar distributions [94]. In contrast, the remaining complex-type glycans present considerable cell-558 
specific differences. This is particularly evident on the gp41 subunit, with CHO-derived material 559 
containing substantially more sialylated structures than HEK-derived BG505 SOSIP.664 (Fig. 3E) [94]. 560 
The abundance of sialic acid is known to impact the antigenicity and immunogenicity of Env. Kong et 561 
al. observed that gp120 expressed in an insect cell line modified to impart asialylated mammalian-562 
type glycans was significantly more immunogenic than sialylated gp120 expressed in HEK cells [150]. 563 
A comparison of virally-derived gp120 produced in PBMCs and gp120 from pseudovirus 564 
produced in HEK cells revealed similar cell-specific differences [183]. Namely, sialylated glycans from 565 
material produced in PBMCs displayed primarily α2-6-linkages, whereas HEK-derived material 566 
displayed only α2-3-linked structures [183]. It can be noted that α2-6-linked sialylated glycans have 567 
previously been associated with anti-inflammatory effects, thus there may be potential immunological 568 
consequences of these structures [184]. 569 
Like oligomannose-type glycans, complex-type glycans have emerged as important in regard 570 
to the formation of bnAb epitopes. Some bnAbs, such as PGT121 display promiscuous recognition of 571 
both oligomannose- and complex-type glycans in glycan arrays [185]. Antibodies such as PGT151 are 572 
dependent on tri- and tetra-antennary structures at the gp120-gp41 interface [186], while α2-6-linked 573 
sialylated hybrid- and complex-type glycans have been implicated in the development and binding of 574 
apex-targeting bnAbs such as PG16 and the CAP256-VRC26 lineage [187-189]. Interactions between 575 
the sialic acid residues of Env and Siglecs (sialic acid-binding immunoglobulin-like lectins) have also 576 
been observed to play an important role in the infection of macrophages, which express low levels of 577 
cell-surface CD4 [190]. Thus, cell-directed glycosylation can play a role in both viral infectivity and 578 
bnAb binding, and understanding the factors influencing complex-type glycosylation may have 579 
implications in guiding immunogen design, for instance when choosing expression cell lines. 580 
4.6 Membrane tethering 581 
The majority of glycan analyses have been performed on soluble Env constructs due to the difficulties 582 
associated with expressing and purifying full-length, membrane-bound Env. Until recently, the impact 583 
of membrane tethering on Env glycosylation had remained largely unaddressed. Analyses of virally-584 
derived Envs, while performed on membrane-bound material, generally did not control for expression 585 
cell-line, known to influence glycosylation processing [173, 174]. However, recent studies by 586 
Rantalainen et al. and Cao et al. directly compare the glycosylation of membrane-bound Envs with 587 
their corresponding soluble SOSIP.664 trimers expressed in the same cell lines. The differences 588 
observed between membrane-bound Env and SOSIP.664 are reminiscent of the differences observed 589 
between viral Env and SOSIP.664, in that sites containing mixed populations of glycans on the soluble 590 
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SOSIP.664 trimer typically displayed only fully processed, complex-type glycan structures on the full-591 
length construct [191]. It was hypothesised that the more complete processing observed on full-length 592 
constructs is due to membrane-bound Env being kept in closer proximity to the membrane-bound 593 
glycosylation enzymes throughout the ER and Golgi (Fig. 3D), as opposed to soluble Env which is 594 
released into the lumen [173, 174]. In line with this hypothesis, membrane-bound CD59 also displays 595 
increased processing compared to its soluble counterpart [192]. 596 
Alternatively, it has been hypothesised that the closer proximity of the membrane to full-597 
length constructs, particularly to gp41, would pose additional steric constraints on Env glycosylation 598 
processing [171]. In support of this hypothesis, Panico et al. observed exclusively oligomannose-type 599 
glycans at the membrane-proximal N88 site on virally-derived Env [178]. A caveat of all the above 600 
studies is that full-length constructs do not contain the SOSIP.664 stabilising mutations, which may 601 
influence glycosylation via a separate mechanism, for example, the speed at which Env transits 602 
through the ER. 603 
4.7 Signal peptide 604 
Like many membrane proteins, immature Env contains a signal peptide at the N terminus responsible 605 
for directing the nascent peptide to the ER, which is subsequently cleaved off prior to transport of the 606 
maturing peptide through the ER and Golgi (Fig. 3B). The signal peptide strongly influences the 607 
processing of Env as it transits through the ER, impacting factors such as trafficking to the ER, the rate 608 
of signal peptide cleavage, and the retention time of Env within the ER [193-198]. Natural variation 609 
exists within the signal peptides of Env. For example, TF viral isolates often over represent His at 610 
position 12 of the signal peptide, a signature not usually observed in chronic phase viral isolates [198]. 611 
Given the influence of the signal peptide on the molecular biology of Env, the laboratory of Fauci 612 
sought to determine the impact of the natural variation observed between the signal peptides isolated 613 
from TF viruses and from a chronically infected patients on the glycosylation, structure and 614 
antigenicity of Env. By creating four constructs containing either the gp120 sequence isolated from a 615 
TF or chronic virus, in combination with either their natural signal peptide, or that of the other virus 616 
(Fig. 3B), Yolitz et al. assessed glycosylation and antigenicity by binding to various lectins and bnAbs 617 
[175]. They found that despite gp120 sequences encoding for the same mature protein, the presence 618 
of a signal peptide from the TF viral isolate resulted in an increase in oligomannose-type glycosylation 619 
(as judged by binding to the Narcissus pseudonarcissus lectin and bnAb 2G12, specific to α-linked 620 
mannose residues), while the presence of a signal peptide from chronic-stage virus increased the 621 
amount of complex-type glycosylation (as judged by binding to Ricinus communis lectin which 622 
preferentially binds structures terminating in galactose).  623 
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The results of Yolitz et al. are in line with the glycan analyses of Go et al., who observed higher 624 
levels of oligomannose-type glycosylation on TF viruses than those isolated from chronically infected 625 
patients [165]. However, a similar comparison of SOSIP.664 trimers isolated from early and late time 626 
points by the Paulson laboratory showed very similar glycan processing [191]. Nevertheless, the 627 
findings of Yolitz et al., implicate the signal peptide, a domain that does not appear in the mature 628 
protein, as a regulator of glycosylation processing. 629 
4.8 Occupancy 630 
Potential N-glycosylation site occupancy has recently emerged as an important aspect of Env 631 
glycosylation. The Paulson laboratory employed site-specific glycan classification analysis to BG505 632 
SOSIP.664 trimers to assess PNGS occupancy [163]. They found that overall occupancy was very high: 633 
all but four of the 28 PNGS (V1/V2 and gp41 sites N190, N197, N618, and N625) were > 90% occupied 634 
and none were < 50% occupied [163]. Extension of their method to native-like trimers derived from 635 
different strains (JR-FL, B41, CRF02_AG_250, 327c, PC64) confirmed that the V1/V2 and gp41 sites 636 
were most susceptible to under-occupancy [174, 191]. The reports concerning occupancy of gp41 637 
sites, particularly N625, seem to vary, perhaps due to methodological or sample variation. For 638 
example, Guttman et al. have reported occupancy < 20% at this site in BG505 and KNH1144 SOSIP.664 639 
trimers [199] which is also compatible with the known epitope of the 35O22 bnAb [82]. 640 
Interestingly, virally-derived and membrane-bound Env trimers are generally more occupied 641 
than their SOSIP.664 counterparts [173, 174, 191]. Although the mechanism through which PNGS 642 
under-occupancy arises is not yet understood, we hypothesise that the codon-optimisation process, 643 
used to increase the yield of recombinant SOSIP.664 trimers, may increase the rate of protein 644 
translation and folding and reduce the chance of an N-glycan being attached [173]. This may be 645 
particularly true of glycans in the V1/V2 region where several PNGS are in close proximity.  646 
4.9 Considerations for immunogen manufacture 647 
All of the above factors influence the glycosylation processing of Env to varying degrees. Although the 648 
extent to which Env immunogens must mimic the native viral envelope spike is not yet known, there 649 
are nevertheless important considerations for immunogen design and manufacture. In particular, 650 
expression cell-type and PNGS under-occupancy may yet emerge as crucial aspects in the cGMP 651 
production of Env immunogens, as under-occupancy may introduce unfavourable, immunodominant 652 
autologous nAb epitopes. This is particularly relevant in light of Wagh et al., observing increased 653 
neutralisation breadth in individuals infected with TF viruses with more intact glycan shields [76]. 654 
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5. Understanding the nature of glycan-dependent bnAb epitopes 655 
The structural characterisation of multiple bnAbs in complex with Env by both X-ray crystallography 656 
and EM has enabled a detailed description of the epitopes of many bnAb (Table 1) [200, 201]. 657 
Furthermore, it has revealed many of the unusual antibody features required for broad neutralisation. 658 
Nevertheless, there remained many unknowns about the precise nature of glycan epitopes. This is, in 659 
part, due to difficulties in resolving extremely heterogeneous glycans with structural techniques that 660 
rely on the averaging of many molecules to reveal the consensus structure [122]. Glycan arrays are 661 
also a useful tool in assessing the glycan-binding properties of bnAbs, though these too have 662 
limitations (e.g. if the epitope comprises protein components). Site-specific glycan analysis has gone 663 
some way to bridging these knowledge gaps. While there is generally good agreement of the precise 664 
structures occupying glycan epitopes between glycan analyses and structural studies/arrays, a few 665 
discrepancies remain. For example, there are several reports on the preference of apex-targeting 666 
bnAbs PG9 and PG16 for complex- or hybrid-type glycans (specifically α2-6-linked sialylated 667 
structures) at the N156 site [187, 188, 202]. However, these structures are seldom seen at this site in 668 
glycan analyses of recombinant, soluble trimers or virally-derived Env [45, 163, 173, 174]. 669 
Table 1. Examples of glycan-targeting broadly neutralising antibodies and their glycan epitopes. 670 
Epitope 
bnAb (and key to 
Fig. 2) 
PNGS Glycan type Refs 
Outer 
domain 
glycans 
PGT130 
 N301, 
N332/N3
34  
Oligomannose 
[203, 
204] 
2G12 
 N295, 
N332, 
N339, 
N392 
Oligomannose, specifically α1-2-linked 
motifs on Man8-9GlcNAc2 structures 
[124-
130] 
VRC-PG05 
 N262, 
N295, 
N448 
Oligomannose [123] 
PGT135 
 N295, 
N332, 
N386, 
N392 
Oligomannose 
[137, 
176, 
204] 
PGT128 
 N156, 
N295, 
N301, 
N332/N3
34  
Oligomannose 
[44, 
136, 
203, 
204] 
PGT122 
 N137, 
N156, 
N301, 
N332 
Oligomannose 
[149, 
200, 
204] 
26 
 
PGT121 
 N137, 
N156, 
N301, 
N332/N3
34 
Oligomannose or complex 
[142, 
185, 
203, 
204] 
BG18 
 N156, 
N332, 
N386, 
N392 
Oligomannose, possibly complex at N156  [205] 
10-1074 
 N156, 
N301, 
N332 
Oligomannose, possibly complex at N156 
[185, 
206] 
V1/V2 
glycans 
PGT145 
 
N160 Oligomannose 
[134, 
204] 
CH04 
 
N160 
Kifunensine abrogates neutralisation 
(can’t tolerate Man9GlcNAc2) 
[207] 
PGDM1400 
 
N160 
Kifunensine reduces/abrogates 
neutralisation (can’t tolerate 
Man9GlcNAc2) 
[208] 
VRC38.01 
 N133, 
N156, 
N160 
N-acetylglucosamine core of N133 [209] 
PG9 and PG16 
 
N173 
(N156), 
N160 
Oligomannose at N160, hybrid or bi-
antennary structures at N156/N173, 
specifically containing α2-6-linked 
terminal sialic acids 
[187, 
188, 
202, 
210-
212] 
CAP256-
VRC26 
(lineage) 
 
N156, 
N160 
Oligomannose at N160, hybrid at N156, 
or bi-, tri-, tetra-antennary structures 
containing α2-6-linked terminal sialic 
acids 
[133, 
189] 
PCT64 
(lineage) 
 N156, 
N160 
Oligomannose, preferentially 
Man5GlcNAc2 
[213] 
CD4bs 
proximal 
3BNC117 
 N197, 
N276 
N-acetylglucosamine cores 
[134, 
149] 
PGV04 (VRC-
PG04) 
 N276, 
N301, 
N363, 
N386 
Enzymatic de-glycosylation doesn’t affect 
binding (no strong glycan-dependence) 
[201, 
214] 
HJ16 
 
N276 N-acetylglucosamine core 
[215-
217] 
IOMA 
 N197, 
N276, 
N363 
Complex, minor contact with 
oligomannose glycan at N363 
[206] 
179NC75  N276 Oligomannose or hybrid† [218] 
VRC01 
 
N276  N-acetylglucosamine core 
[131, 
149] 
gp120/gp41 
interface 
8ANC195 
 N234, 
N276, 
N637 
Kifunensine did not affect neutralisation 
(can tolerate Man9GlcNAc2) 
[219, 
220] 
27 
 
PGT151 
 
N611, 
N637 
Complex, specifically tri- and tetra-
antennary structures 
[186, 
221, 
222] 
VRC34.01 
 
N88 
Kifunensine, swainsonine or GnTI−/− cells‡ 
minimally affect neutralisation (not 
dependent on complex structures) 
[223] 
ACS202 
 
N88 
Kifunensine, or GnTI−/− cells minimally 
affect neutralisation (not dependent on 
complex structures) 
[224] 
35O22 
 N88, 
N230, 
N241 
Oligomannose 
[149, 
225] 
Footnotes: 671 
† In Freund et al., 2015, the loss of binding of 179NC75 following expression of BG505 SOSIP.664 672 
trimers with kifunensine was used to argue a dependency on complex-type glycans. However, they 673 
also report a loss of binding to gp120 after digestion with Endoglycosidase H (which cleaves 674 
oligomannose- and hybrid-type glycans). This suggests that 179NC75 recognises Man8-5GlcNAc2 or 675 
hybrid-type structures. In line with this, site-specific glycan analysis of BG505 SOSIP.664 trimers 676 
reports predominantly Man8-5GlcNAc2 glycans at the N276 site, with a small population of hybrid-type 677 
structures [45].  678 
‡ Treatment with swainsonine (α-mannosidase II inhibitor) results in oligomannose- and hybrid-type 679 
glycosylation. Expression in GnTI−/− cells (deficient in N-acetylglucosaminyltransferase I) results in 680 
Man5-9GlcNAc2 structures only. 681 
 682 
6. Beyond antigenic mimicry 683 
Native-like trimers are excellent structural mimics of viral Env, display similar glycosylation profiles, 684 
and are capable of binding bnAbs. Yet immunogenicity studies with native-like trimers have only 685 
routinely elicited autologous Tier-2 nAbs and heterologous Tier-1 nAbs [107, 116-121]. Weakly 686 
neutralising heterologous Tier-2 antibodies have also been reported in rabbits [104]. With the 687 
exception of cows (whose antibodies naturally contain very long HCDR3), the potent bnAbs required 688 
for a protective vaccine have not yet been generated via immunisation with native-like trimers [58]. 689 
The elicitation of bnAbs against the envelope spike will inevitably be challenging. Broadly neutralising 690 
epitopes are broad due to their conserved nature, though conservation generally correlates with poor 691 
immunogenicity as otherwise the epitope would have been selected against by immune pressure. In 692 
this section, we will address some of the strategies aimed at increasing the immunogenicity of this 693 
target. 694 
6.1 Mimicry of glycan epitopes: chemical approaches 695 
The first of many glycan-binding bnAbs to be discovered was 2G12. To date, this the only bnAb 696 
identified to exclusively bind glycans. The 2G12 antibody recognises clusters of α1-2-linked mannose 697 
motifs present on the Man8-9GlcNAc2 structures of the IMP (Fig. 2) [124-130]. Glycan based vaccine 698 
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strategies have thus far centred on the design of immunogens that mimic the 2G12 epitope. Several 699 
groups have created immunogens displaying multivalent, chemically synthesised oligomannose-type 700 
glycans attached to various scaffolds, including: carbohydrate, cholic acid, cyclic peptide, dendrimer, 701 
DNA, and gold (reviewed in Wang, 2013 [226]). Although many of these constructs are able to bind 702 
2G12, and could elicit antibodies with specificity to oligomannose-type glycans, none have induced 703 
antibodies capable of neutralising HIV-1. This may be due to the inability of these antibodies to 704 
recognise clusters of oligomannose-type glycans as they are presented on Env, perhaps due to their 705 
non-domain-exchanged structures. Domain-exchange (at least for 2G12) is a requirement for HIV-1 706 
neutralisation [227]. 707 
The mimicry of other glycan-targeting bnAb epitopes has been explored with the design of 708 
peptide-based immunogens. Glycopeptides based on the V1/V2 region, containing the N156 and N160 709 
PNGS, are capable of binding both apex targeting bnAbs and their unmutated common ancestors [202, 710 
228, 229]. Similarly, glycopeptides based on the V3 region, containing the N332 PNGS, bound outer 711 
domain targeting bnAbs such as PGT128 [230]. In immunogenicity studies, V3 glycopeptides elicited 712 
antibodies capable of binding gp120 but unable to neutralise virus [230, 231]. The failure of antigenic 713 
mimics of bnAb epitopes to induce bnAbs further highlights the complicated relationship between the 714 
antigenicity and immunogenicity of these epitopes. 715 
6.2 Mimicry of glycan epitopes: biological approaches 716 
A potential failure of the above strategies may be that, while the oligomanose-type glycans of the HIV-717 
1 glycan are not typically observed on mammalian glycoproteins, they are still fundamentally ‘self’ 718 
structures. As noted above, this poses a challenge for the development of glycan-targeting bnAbs, as 719 
cross-reactive B cells are likely to be deemed autoreactive and will be negatively selected for. The fact 720 
that bnAbs generally do not arise until after several years of infection could support the notion that 721 
they are operating at the edge of immunological tolerance, or may simply reflect the long maturation 722 
process. However, tolerance to self-structures can be broken. For example, in some cases, infection 723 
with C. jejuni elicits an antibody response against its bacterial lipooligosaccharides that is able to bind 724 
nearly identical structures on the gangliosides of the peripheral nervous system (Fig. 6A) [148]. The 725 
resulting autoimmune disease, Guillain-Barré syndrome, provides proof of concept that 726 
immunological tolerance to ‘self’ glycans can be broken by exposure to micro-organisms bearing 727 
similar structures [42].  728 
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 729 
Figure 6. Antigenic mimicry in autoimmune disease and HIV-1 vaccine design. (A) Antigenic mimicry 730 
of lipooligosaccharides (LOS) from Campylobacter jejuni causes Guillain-Barré syndrome, an 731 
autoimmune response against the GM1 ganglioside in the peripheral nervous system (PNS). (B) LOS 732 
from Rhizobium radiobacter Rv3 and Saccharomyces cerevisiae deficient in the Mnn1 gene display 733 
glycan structures terminating in α1-2-linked mannose residues, mimicking the 2G12 epitope on HIV-734 
1. GalNAc = N-acetylgalactosamine, Glc = gluscose, GlcN = glucosamine, KDO = 2-keto-3-deoxy-D-735 
manno-octulosonic acid. Figure adapted from Scanlan et al., 2007 [42]. 736 
 737 
It was hypothesised that 2G12 may have originally evolved to recognise high-mannose 738 
structures on pathogens other than HIV-1 [42]. Scanlan explored this further by assessing the reactivity 739 
of 2G12 to various yeast species [146]. Yeast typically display high-mannose structures that comprise 740 
an α1-6-linked mannnose backbone from which branch repetitive α1-2-linked mannose motifs (i.e. a 741 
key feature of the 2G12 epitope), sometimes capped with α1-3-linked mannose residues. Of the yeast 742 
species tested, 2G12 was able to bind to two, binding Candida albicans with similar affinities to that 743 
of gp120 [146, 232]. This interaction was glycan dependent as binding was inhibited by D-fructose, a 744 
known ligand for the 2G12 binding site. Additionally, a non-glycan-dependent control bnAb was 745 
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unable to bind any of the yeasts. Thus, the 2G12 antibody may equally well be described as an anti-746 
Candida antibody with cross-reactivity to HIV-1 [146]. 747 
Scanlan went on to formally elucidate the relationship between the antigenicity and 748 
immunogenicity of yeast glycosylation [233]. Saccharomyces cerevisiae deficient in mnn1, the gene 749 
responsible for the α1-3-linked mannnose caps, displays mannans terminating in the α1-2-linked 750 
mannose motif (Fig. 6B). Immunisation of rabbits with S. cerevisiae ∆mnn1 elicited antibodies with 751 
similar glycan specificities to 2G12. Furthermore, the sera displayed weakly neutralising activity 752 
against HIV-1 [233]. The Doms laboratory also investigated using yeast as an HIV-1 immunogen. By 753 
knocking-out three genes they produced S. cerevisiae displaying predominantly Man8GlcNAc2 glycan 754 
structures. Although these yeasts now displayed a ‘self’ glycan structure, immunisation of rabbits 755 
elicited oligomannose-specific antibodies, capable of binding monomeric gp120, but unable to 756 
neutralise the virus [234]. As mentioned previously, an explanation for this apparent contradictory 757 
result may be that while the elicited antibodies were capable of recognising isolated oligomannose-758 
type glycans, they were not able to recognise densely packed clusters of oligomannose-type glycans 759 
as they are presented on Env. Thus, a logical next step may be to present immunogenic yeast glycan 760 
structures in the context of Env, for instance, by expressing Env in yeast. The resulting immunogens 761 
should display clusters of ‘non-self’ glycans capable of breaking immunological tolerance to the 762 
clusters of oligomannose-type glycans present on Env.  763 
A similar phenomenon has been observed by the Pantophlet laboratory. As per S. cerevisiae 764 
∆mnn1 mannans, the lipooligosaccharides of Rhizobium radiobacter Rv3 bacteria contain a glycan 765 
motif analogous to the 2G12 epitope on HIV-1 (Fig. 6B) [235, 236]. Immunisation of mice with R. 766 
radiobacter Rv3 also generated antibodies capable of weakly cross-reacting with HIV-1 [235, 237], 767 
representing another candidate micro-organism to investigate for a potential HIV-1 glycan-based 768 
vaccine. 769 
6.3 Mimicking bnAb development in natural infection 770 
The development of bnAbs in a subset of infected individuals typically only occurs after a few years of 771 
infection. Neutralising antibodies, however, arise early in infection, and exert a considerable selection 772 
pressure on the virus. Repeated rounds of viral escape and antibody evolution ultimately drive the 773 
development of nAb breadth [70, 132, 133]. The discovery that native-like trimers can induce 774 
autologous Tier-2 nAbs could therefore be an important first step towards development of bnAbs. 775 
Accordingly, a line of research is to attempt to mimic the development of bnAbs in natural infection 776 
by immunising with a longitudinal sequence of trimers based on the Envs from an infected individual 777 
who went on to generate bnAbs. An in-depth understanding of viral and antibody co-evolution 778 
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throughout the course of natural infection will no doubt prove invaluable in aiding the design of such 779 
immunisation regimens [132, 191, 213, 238, 239]. 780 
An alternative, albeit closely linked, approach is to design immunogens specifically targeted 781 
to initiate bnAb development. As noted previously, the development of bnAbs requires the activation 782 
of B cell lineages expressing gl-bnAbs, which are typically very poor at binding Env trimers [61-64]. 783 
This approach therefore involves the modification of immunogens in order to better engage gl-bnAbs 784 
[240], usually by the deletion of PNGS and variable loops to remove the steric occlusions which 785 
prevent gl-bnAb binding [241-243]. The laboratories of Schief and Nussenzweig have reported that 786 
BG505 SOSIP trimers containing, among other mutations, N133 and N137 PNGS deletions, are able to 787 
bind a germline-reverted version of the outer domain glycan-targeting bnAb, PGT121 [244]. 788 
Immunisation of mice engineered to express the predicted germline of PGT121 with this trimer, prior 789 
to boosting with a sequence of immunogens containing decreasing modifications, was able to elicit 790 
heterologous Tier-2 neutralising responses [245]. This provides proof of concept that immunisation 791 
with specifically designed immunogens can initiate bnAb development. There is, however, an 792 
apparent conflict between the need to delete PNGS sites in order to initiate bnAb development, and 793 
the recent observation that bnAbs were more likely to develop in individuals infected with isolates 794 
containing more intact glycan shields [76]. 795 
7. Conclusions 796 
Antigenic mimicry is fundamental to most licensed vaccines. It is widely acknowledged that a 797 
protective HIV-1 vaccine will be based on the mimicry of the HIV-1 envelope spike, the sole target for 798 
bnAbs raised during infection. In addition to protein mimicry, Env-based immunogens will likely have 799 
to exhibit glycan mimicry, as many of the most potent bnAbs isolated to date recognise glycan 800 
structures within their epitopes. Thus, the characterisation of glycan epitopes, and an understanding 801 
of the principles governing their correct processing is needed in order to continue to guide the rational 802 
design of HIV-1 immunogens. Structural constraints imposed by the formation of native-like trimers 803 
restricts aspects of glycosylation processing, thus glycan analysis can help distinguish between native-804 
like and non-native immunogens. However, native-like immunogens alone aren’t sufficient to induce 805 
bnAbs. As broadly neutralising epitopes are inherently immunoquiescent it is likely that additional 806 
strategies will be required in order to boost their immunogenicity.  807 
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